FIGURE
Fig. 7
- ID
- ZDB-FIG-220816-69
- Publication
- Herman et al., 2022 - The EGFR/ErbB inhibitor neratinib modifies the neutrophil phosphoproteome and promotes apoptosis and clearance by airway macrophages
- Other Figures
- All Figure Page
- Back to All Figure Page
Fig. 7
Neratinib treatment reduces the levels of cytokines IL-6 and KC in BAL in the induction dosing model of lung disease. Cytokines were measured in BAL supernatant by ELISA. Interleukin-6 (IL-6) and KC were reduced in neratinib-treated mice in the induction dosing model (A, B), whereas these were unchanged in the therapeutic dosing model (C, D). Each data point represents data from one mouse; bars show mean ± standard deviation. Unpaired t-tests were used for statistical analysis; p-values were indicated. |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Front Immunol